Small molecule · Inhibitor of fibroblast growth factor receptor 3 (FGFR3) · developed by Tyra Biosciences
Dabogratinib (TYRA-300) is an orally bioavailable, selective inhibitor of fibroblast growth factor receptor 3 (FGFR3), a receptor tyrosine kinase. It binds FGFR3 activating alterations, including the V555L/M gatekeeper mutants, to block FGFR3-mediated signaling. It is being studied in urothelial carcinoma and other solid tumors with FGFR3 alterations.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07265947 | Phase 2 | Low Grade Upper Tract Urothelial Carcinoma | Recruiting | TYRA |
| NCT06995677 | Phase 2 | Low-grade NMIBC | Recruiting | TYRA |
| NCT06842355 | Phase 2 | Achondroplasia | Recruiting | TYRA |
| NCT05544552 | Phase 1/2 | Locally Advanced Urothelial Carcinoma | Active not recruiting | TYRA |
| NCT06006702 | Phase 1 | Healthy | Active not recruiting | TYRA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced Solid TumorAdvanced Urothelial CarcinomaBladder CancerFGFR3 Gene AlterationFGFR3 Gene MutationHealthyLocally Advanced Urothelial CarcinomaMetastatic Urothelial CarcinomaNon-muscle-invasive Bladder CancerSolid TumorSolid Tumor, AdultUrinary Tract CancerUrinary Tract CarcinomaUrinary Tract Tumor
Updated Nov 1, 2026. Something wrong or missing? Report it on the TYRA page.
See TYRA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
TYRA catalysts and pipeline →